Late-Breaking Data Show Breadth of Abbott s Minimally Invasive Structural Heart Technologies streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Five late-breaking presentations at TCT 2022 highlight the impact of Abbott s structural heart devices to repair or replace heart valves and close openings in the heartNew data reinforce the safety.
Three-fourths of patients had at least a two-grade reduction in tricuspid regurgitation, and 88% were alive 1 year after treatment with the experimental device.
email article
Progress continues to be made on new transcatheter devices for the treatment of severe mitral and tricuspid regurgitation, investigators reported.
Several valve repair and replacement technologies, designed as alternatives to surgery in high-risk patients, had promising early results presented at this year s virtual European Association of Percutaneous Cardiovascular Interventions (EuroPCR) meeting.
The larger pivotal trials for these devices are not expected to be completed for at least another few years. As such, the following all remain investigational devices in the U.S.
Tendyne in Mitral Valve Replacement
Operators reported good real-world experience with Tendyne, a tri-leaflet bioprosthetic valve from Abbott, in registry data going out to 30 days.